medigraphic.com
ISSN 0016-3813 (Print)

2019, Number 5

<< Back Next >>

Gac Med Mex 2019; 155 (5)

Perfil clínico-epidemiológico de las defunciones por influenza con antecedente de vacunación oportuna, México 2010-2018

Kuri-Morales PA, Díaz del Castillo-Flores G, Castañeda-Prado A, Pacheco-Montes SR

Language: Spanish
References: 20
Page: 457-463
PDF size: 185.87 Kb.


ABSTRACT

Introduction: Influenza epidemics are of higher risk at the extremes of life and in people with comorbidities. Effective vaccination prevents the occurrence of serious cases and decreases mortality. Objective: To describe deaths from influenza with a history of timely vaccination, from the 2010 to the 2018 season in Mexico. Method: Cross-sectional, descriptive study where the Influenza Epidemiological Surveillance System database was used. Results: From 2010 to 2018, 65 vaccinated individuals died from influenza, from which 55% of cases (n = 36) were due to type A (H1N1), 51% (n = 33) were females, median age was 57 years, 21 % (n = 14) did not meet the operational definition of influenza-like illness or severe acute respiratory infection, 83% (n = 54) had at least one comorbidity, with the most common being diabetes mellitus and hypertension (32% each); 55% (n = 36) of deaths received antiviral treatment and only 8% (n = 5) had no comorbidities and received treatment with oseltamivir. Conclusions: Deaths from influenza with timely vaccination represent a very low percentage of the totality. Vaccination against influenza has been a specific prevention strategy that decreases disease burden.


REFERENCES

  1. Fact Sheet: Flu [en línea]. Suiza: Organización Mundial de la Salud; 2018.

  2. Hutchinson EC. Influenza virus. Trends Microbiol. 2018;26:809-810.

  3. Antecedentes del ACIP 2017-2018 [en línea]. EE. UU.: Centers for Disease Control and Prevention; 2018.

  4. Nichol KL. Heterogeneity of influenza case definitions and implications for interpreting and comparing study results. Vaccine. 2006;10:6726-6728.

  5. Petrie JG, Ohmit SE, Johnson E, Truscon R, Monto AS. Persistence of antibodies to influenza hemagglutinin and neuraminidase following one or two years of influenza vaccination. J Infect Dis. 2015;212:1914-1922.

  6. Skowronski DM, Tweed SA, De Serres G. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? J Infect Dis. 2008;197(4):490-502.

  7. Castilla J, Martínez-Baz I, Martínez-Artola V, Reina G, Pozo F, García-Cenoz M, et al. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill. 2013;18:20388.

  8. Pebody R, Andrews N, McMenamin J, Durnall H, Ellis J, Thompson CI, et al. Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection. Euro Surveill. 2013;18:20389.

  9. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60:1-24.

  10. Manual para la vigilancia epidemiológica de influenza. México: Secretaría de Salud/Dirección General de Epidemiología; 2014.

  11. Manual de procedimientos estandarizados para el sistema estadístico epidemiológico de las defunciones (SEED). México: Secretaría de Salud/ Dirección General de Epidemiología; 2012.

  12. Yang KC, Hung HF, Chen MK, Chen SL, Fann JC, Chiu SY, et al. Cost-effectiveness analysis of universal influenza vaccination: application of the susceptible-infectious-complication-recovery model. Int J Infect Dis. 2018;73:102-108.

  13. Ruiz-Matus C, Kuri-Morales P, Narro-Robles J. Behavior of influenza seasons in Mexico from 2010 to 2016: analysis and prospective. Gac Med Mex. 2017;153:205-213.

  14. Yang JH, Huang PY, Shie SS, Yang S, Tsao KC, Wu TL, et al. Predictive symptoms and signs of laboratory-confirmed influenza: a prospective surveillance study of two metropolitan areas in Taiwan. Medicine (Baltimore). 2015;94:e1952.

  15. Encuesta Nacional de Salud y Nutrición de Medio Camino 2016. Informe final de resultados. México: Instituto Nacional de Salud Pública; 2016.

  16. Neidich SD, Green WD, Rebeles J, Karlsson EA, Schultz-Cherry S, Noah TL, et al. Increased risk of influenza among vaccinated adults who are obese. Int J Obes (Lond). 2017;41:1324-1330.

  17. Lineamientos Generales del Programa de Vacunación Universal y Semanas Nacionales de Salud 2018. [en línea]. México: Secretaría de Salud/Centro Nacional para la Salud de la Infancia y Adolescencia; 2018.

  18. Sellers SA, Hagan RS, Hayden FG, Fischer WA. The hidden burden of influenza: A review of the extra‐pulmonary complications of influenza infection. Influenza Other Respir Viruses. 2017;11:372-393.

  19. Mazagatos C, Delgado-Sanz C, Oliva J, Gherasim A, Larrauri A, Spanish Influenza Surveillance System. Exploring the risk of severe outcomes and the role of seasonal influenza vaccination in pregnant women hospitalized with confirmed influenza, Spain, 2010/11-2015/16. PLoS ONE. 2018;13:e0200934.

  20. Memoli MJ, Athota R, Reed S, Czajkowski L, Bristol T, Proudfoot K, et al. The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. Clin Infect Dis. 2014;58:214-224




2020     |     www.medigraphic.com